For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and the formulated version represents a significant advancement . These groundbreaking therapies preserve the transthyretin protein, halting its harmful build-up and reducing the severity of the disease . People are now experiencing